Vericel VCEL
NASDAQ VCEL
$40.31 -0.30 (-0.74%)
As of: Sep 30, 2026 · 10:22 AM EDT

Vericel (VCEL) Current Deferred Revenue (2017 - 2018)

Updated

Vericel's Current Deferred Revenue came in at $534,000 for Q3 2018, up 6.2% from the prior quarter.

Analysis

Vericel (VCEL) Current Deferred Revenue (2017 - 2018) Analysis & Trends

At the end of FY2017, Vericel's Current Deferred Revenue was $420,000.

  • Business Quant data shows VCEL's Current Deferred Revenue at $503,000 (Q2 2018), $426,000 (Q1 2018) and $420,000 (Q4 2017) in the three quarters before Q3 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Vericel 2.06 Bn 1.48 Bn 56.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 534,000.00
Jun 30, 2018 503,000.00
Mar 31, 2018 426,000.00
Dec 31, 2017 420,000.00
API Access

Vericel Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=VCEL&period=max&api_key=YOUR_API_KEY